Last reviewed · How we verify
AB-PA01
AB-PA01 is a bacteriophage therapeutic that targets and lyses pathogenic bacteria to treat infections.
AB-PA01 is a bacteriophage therapeutic that targets and lyses pathogenic bacteria to treat infections. Used for Chronic Pseudomonas aeruginosa respiratory tract infections in cystic fibrosis patients.
At a glance
| Generic name | AB-PA01 |
|---|---|
| Sponsor | Armata Pharmaceuticals, Inc. |
| Drug class | Bacteriophage therapeutic |
| Target | Pseudomonas aeruginosa |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
AB-PA01 is a phage-based therapeutic designed to selectively infect and destroy Pseudomonas aeruginosa, a multidrug-resistant pathogen. The bacteriophage approach offers an alternative to conventional antibiotics by using naturally occurring viruses that specifically target bacterial cells, potentially reducing the development of antibiotic resistance.
Approved indications
- Chronic Pseudomonas aeruginosa respiratory tract infections in cystic fibrosis patients
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |